AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18046883
Drug: Alpha-2 agonists
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-2 agonists (A2Ags)
Trial: 11601508
Drug: Intravenous 10%
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10% dextran 40
Trial: 9240678
Drug: Wallstent with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wallstent with periprocedural heparin
Trial: 9240678
Drug: Wallstent without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wallstent without periprocedural heparin
Trial: 9240678
Drug: Palmaz stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmaz stent with periprocedural heparin
Trial: 9240678
Drug: Palmaz stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmaz stent without periprocedural heparin
Trial: 2955033
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms ethinyl oestradiol daily (OC)
Trial: 27474356
Drug: Prasugrel (2-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (2-30 mg single administration)
Trial: 27474356
Drug: Prasugrel (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (2.5-10 mg multiple administration)
Trial: 27474356
Drug: Prasugrel (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (up to 30 mg single administration and up to 10 mg maintenance dose)
Trial: 24456422
Drug: L-PGDS
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PGDS
Trial: 16310197
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (300 ml for 15 days)
Trial: 16310197
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (300 ml for 15 days)
Trial: 10762178
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg x kg(‐1) over 1 h, followed by 5.4 mg x kg(‐1) x h(‐1) for 23 h)
Trial: 10762178
Drug: Nimodipine (0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (0.015 mg x kg(‐1) x h(‐1) for 2 h followed by 0.03 mg x kg(‐1)h(‐1) for 7 days)
Trial: 10762178
Drug: No medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medical treatment (Control group)
Trial: 1483668
Drug: Neomycin sulfate
RxNorm normalized name: Neomycin Sulfate
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin sulfate (6 g per os)
Trial: 29126314
Drug: Standard single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard single-agent therapy
Trial: 27154847
Drug: Filgrastim-stimulated marrow
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim-stimulated marrow (G-BM)
Trial: 27154847
Drug: Filgrastim-mobilized peripheral
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim-mobilized peripheral blood (G-PB)
Trial: 21056464
Drug: Rivastigmine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (1.5 mg twice daily increasing to 6 mg twice daily) as an adjunct to usual care with haloperidol
Trial: 21056464
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as an adjunct to usual care with haloperidol
Trial: 17785930
Drug: Efonidipine 20‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efonidipine 20‐60 mg twice daily
Trial: 17785930
Drug: Amlodipine 2.5‐7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5‐7.5 mg once daily
Trial: 7526676
Drug: Celiprolol (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (selective beta blocker) for 8 weeks
Trial: 19466504
Drug: Ciprofloxacin (CIP)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CIP) at 300 mg twice daily by intravenous drip infusion
Trial: 19466504
Drug: Imipenem/cilastatin (IPM/CS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (IPM/CS) at 500 mg twice daily by intravenous drip infusion
Trial: 343993
Drug: 0.1% halcinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% halcinonide applied once daily
Trial: 343993
Drug: 0.05% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% betamethasone dipropionate cream applied twice daily
Trial: 26538383
Drug: Not the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not the Ice Cream Van (NTICV)
Trial: 19191743
Drug: TSH levels
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH levels (0.3-10.0 mIU/L)
Trial: 28437263
Drug: CHO group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO group received oral CHO (400 ml) the prior evening and 2 to 3 hours before surgery.
Trial: 25675222
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel injection
Trial: 25675222
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water injection
Trial: 16828500
Drug: 0.3-mg pegaptanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3-mg pegaptanib continued for 48 weeks (8 injections)
Trial: 16828500
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care or discontinuation of pegaptanib
Trial: 9603290
Drug: 0.25% nipradilol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% nipradilol (N = 9) twice daily for 15 days
Trial: 9603290
Drug: 0.01% bunazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% bunazosin (N = 10) twice daily for 20 days
Trial: 8256008
Drug: Transdermal nitroglycerine
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerine (TNG) - 2 cm of NTG gel administered once a day
Trial: 3899248
Drug: Single phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single phenol injection
Trial: 3899248
Drug: Multiple phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple phenol injection
Trial: 31888708
Drug: Cognitive behavioral-physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral-physical therapy (CBPT) intervention
Trial: 29384722
Drug: ADT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT in combination with docetaxel 75 mg/m2 for up to six cycles
Trial: 29384722
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy for high-volume disease (n = 513)
Trial: 29384722
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy for low-volume disease (n = 277)
Trial: 27105868
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg resveratrol
Trial: 18785409
Drug: rhGM‐CSF hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF hydrogel (100 microg/10 g/100 cm2/d)
Trial: 9625104
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1200 mg elemental Ca/d)
Trial: 31418151
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 1 g/kg of organic mineral mixture
Trial: 31418151
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 0.5 g/kg of organic mineral mixture
Trial: 31418151
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + organic mineral mixture (0.5 g/kg and 1 g/kg)
Trial: 25867075
Drug: No written
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No written instructions other than prescriptions
Trial: 21148516
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (8 oz of 27% cranberry juice twice daily)
Trial: 19351303
Drug: Chemotherapy Symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy Symptom Assessment Scale
Trial: 14643116
Drug: Ximelagatran (fixed-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (fixed-dose, 36 mg twice daily)
Trial: 14643116
Drug: Warfarin (adjusted-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted-dose, INR 2.0-3.0)
Trial: 25040321
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of sumatriptan subcutaneously
Trial: 9484515
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of dihydroergotamine intramuscularly
Trial: 7524381
Drug: Prostaglandin- and
RxNorm normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin- and kininogenesis inhibitors (acelysin and kontrykal)
Trial: 1326348
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg rifabutin
Trial: 1326348
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg rifabutin
Trial: 1326348
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg rifabutin
Trial: 1326348
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg rifabutin
Trial: 1326348
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg rifampicin
Trial: 1326348
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg rifampicin
Trial: 3885634
Drug: Postoperative radio-
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative radio- and chemotherapy (group A)
Trial: 3885634
Drug: Combined longterm
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined longterm chemotherapy (group B)
Trial: 16705846
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified what the control treatment was)
Trial: 31671938
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200 mg/m2/day for 5 days during six 28-day cycles)
Trial: 31215838
Drug: SFTSV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFTSV vaccine
Trial: 21859323
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (baseline) and subgingival debridement (3-month follow-up)
Trial: 21859323
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment and supragingival prophylaxis (3-month follow-up)
Trial: 19208404
Drug: Modafinil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (up to 300 mg/day for 4 weeks)
Trial: 17389710
Drug: Exercise (EX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise (EX), 20% increase in energy expenditure through daily exercise (n = 18)
Trial: 16229115
Drug: New letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: New letrozole preparation
Trial: 7768250
Drug: 200-300 mg
RxNorm normalized name: allopurinol 300 MG / lesinurad 200 MG [Duzallo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-300 mg sustained release diltiazem (200-300 SR) administered once daily
Trial: 7768250
Drug: Standard diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diltiazem (D) given three or four times daily
Trial: 2100165
Drug: Bupranolol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupranolol 0.25% in an oily solution
Trial: 27600367
Drug: Tofacitinib re-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib re-treatment (5 mg and 10 mg)
Trial: 24880907
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group 1 (n = 66) received 125 ml of ONS twice per day, at 12 and 17 o'clock
Trial: 24880907
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group 2 (n = 80) received 62 ml of ONS four times a day, at 8, 12, 17 and 20 o'clock
Trial: 24880907
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group (n = 88) offered ONS 125 ml twice per day in between meals
Trial: 21069516
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg sustained release)
Trial: 21069516
Drug: Light treatment
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light treatment (0700 to 0800 hours)
Trial: 21069516
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg sustained release) plus Light treatment
Trial: 17213754
Drug: ERr 731
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ERr 731 (1 enteric coated tablet daily for 12 weeks)
Trial: 17213754
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet daily for 12 weeks)
Trial: 2502048
Drug: Peripheral Parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral Parenteral Nutrition (PPN)
Trial: 900915
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg orally
Trial: 900915
Drug: Cephalexin 250
RxNorm normalized name: cephalexin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 250 mg orally
Trial: 1375713
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with collagen sponge implant containing 100 micrograms of antimetabolite (5‐fluorouracil or bleomycin)
Trial: 15918297
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with a monomeric allergoid of Cupressus arizonica pollen
Trial: 17577005
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (6 trials, 2900 participants)
Trial: 10507957
Drug: Aspirin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (6 trials, 3119 participants)
Trial: 10507957
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (5 trials, 2837 participants)
Trial: 30961342
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate treatment group
Trial: 30508196
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg once daily
Trial: 22264885
Drug: 0.1% fluorometholone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% fluorometholone 3 times a day (steroid group)
Trial: 22264885
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of steroid eye drops (no steroid group)
Trial: 19429734
Drug: Self-reported adherence-satisfaction
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported adherence-satisfaction with taking medication
Trial: 18257436
Drug: Adjuvant ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant ultrasound therapy
Trial: 18257436
Drug: NSAIDs, exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs, exercise therapy, manipulative therapy, corticosteroid injection, acupuncture
Trial: 1451219
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of glucose-free lidocaine 2%
Trial: 1451219
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of glucose-free lidocaine 2%
Trial: 1451219
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of glucose-free lidocaine 2%
Trial: 3881598
Drug: 21-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21-day treatment
Trial: 31805855
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural analgesia with 6 ml/h of 0.25% bupivacaine during surgery and 6 ml/h of 0.125% bupivacaine for 24 h post-surgery.
Trial: 28089476
Drug: ADMA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADMA levels (0.9±0.2μmol/L)
Trial: 28089476
Drug: Highest ADMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest ADMA quintile (≥1.07μmol/L)
Trial: 28089476
Drug: SDMA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDMA levels (4.3±1.4μmol/L)
Trial: 26149722
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS messages (direct, PIN-protected, coded) and transportation reimbursements (about $6 USD) for participants returning within seven days.
Trial: 24047438
Drug: Single-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose azithromycin (AZT) 1000 mg orally
Trial: 24047438
Drug: Azithromycin (AZT)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZT) 500 mg daily for 9 and 14 days
Trial: 24047438
Drug: Doxycycline (DOX)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline (DOX) 200 mg for 21 days
Trial: 20819978
Drug: Psilocybin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (0.2 mg/kg)
Trial: 17944893
Drug: Normal hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal hospital diet plus 400‐mL oral nutritional supplements daily for 6 weeks
Trial: 15547534
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter balloon inflated with 80 mL of sterile saline
Trial: 15547534
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter balloon inflated with 30 mL of sterile saline
Trial: 3305744
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality approach in rectal carcinoma patients (stages B2 and C)
Trial: 22043463
Drug: Flapless implant
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flapless implant placement
Trial: 29234747
Drug: Flap implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flap implant placement
Trial: 19673983
Drug: Biophage-PA (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biophage-PA (therapeutic bacteriophage preparation)
Trial: 16495395
Drug: Itopride 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 50 mg three times daily
Trial: 17965059
Drug: Itopride 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 100 mg three times daily
Trial: 16495395
Drug: Itopride 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 200 mg three times daily
Trial: 16495395
Drug: Itopride (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride (combined doses)
Trial: 16495395
Drug: Itopride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride (100 mg and 200 mg)
Trial: 14616590
Drug: AM149 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM149 1% (new formulation of propofol)
Trial: 14616590
Drug: Disoprivan 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disoprivan 1% (standard formulation of propofol)
Trial: 1637794
Drug: Fat/cholesterol supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat/cholesterol supplement (31 g fat, 650 mg cholesterol)
Trial: 1637794
Drug: Fat/cholesterol supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat/cholesterol supplement
Trial: 1637794
Drug: Fat-free supplement
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-free supplement
Trial: 3881654
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (azathioprine, prednisone, antithymocyte immunoglobulin)
Trial: 31058977
Drug: HSV529 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV529 vaccine